One of Whoop's new wearables has a bug so bad the company is issuing replacements
Whoop's new screen-less, fitness-focused Whoop MG wearable might have a major bug that can leave the device unusable, according to reports from Android Police and TechIssuesToday . Whoop launched the Whoop MG and Whoop 5.0 at the beginning of May, the company's first major hardware release since it launched the Whoop 4.0 in 2021.
According to complaints on Whoop's community forums and X, after setting up a Whoop MG, the wearable can mysteriously became unresponsive hours later, refusing to connect to a smartphone even when it should be charged. "I wore it for about 20 hours or so, but then it suddenly disappeared from the app, no sensor lights on, nothing appearing in the app," one new Whoop MG owner shared on Reddit. On the company's forums, Whoop suggests trying things like charging the MG, reconnecting it to your phone or resetting the wearable to see if that fixes things. Whoop owners have also been directed to contact Whoop's Support team, and multiple faulty Whoop MG owners report that they're being sent replacement wearables.
Engadget has contacted Whoop to get a sense for how widespread this issue is and what the company is doing to address it. We'll update this article if we hear back.
Unlike other companies, Whoop doesn't expect customers to buy a fitness tracker and then pay a subscription; Whoop's subscription fee is inclusive of its hardware. With the Whoop 5.0 and Whoop MG, the company is also hoping to expand the number of metrics it tracks beyond just activity and sleep tracking to things like real-time stress monitoring and, in the case of the MG, blood pressure and ECG readings. What features you're able to access ultimately depends on both the wearable you have and the subscription you're paying for, though.
To access the Whoop MG in particular, you have to pay $359 annually, which starts to feel pretty egregious when the wearable might not work. Prior to this issue, Whoop was also caught denying free hardware upgrades to existing customers after previously suggesting it would send out new wearables to anyone who'd been a member for six months or more. Whoop reversed that decision a few days later.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WIRED
4 hours ago
- WIRED
The Whoop MG Tells You How Fast You're Aging
In a sea of nearly identical fitness trackers, Whoop stands apart. Since it started in 2012, the company has understood that the hardware was secondary to software. For a pricey monthly membership, you get access to a (theoretically) never-ending series of new features in the Whoop app, and the company throws in the small, screenless sensor for free. This was once a pretty good bargain, but for the past several years, Whoop hasn't done much. In 2023, the company released its OpenAI-powered personalized fitness service, Whoop Coach. As with most other AI-enabled fitness services, you had to think really hard about how to frame your questions to get useful advice. I didn't find it particularly helpful. This year, the company finally released an updated Whoop that comes with a bevy of new features that make it a much more versatile tracker for people who don't post their gains every day. Most notably, it has a proprietary algorithm for blood pressure tracking. I've been testing the new Whoop MG for a few weeks now, and it reminded me why people like this tracker so much. Screen-Free Solution Photograph: Adrienne So If you're not familiar with a Whoop tracker, it's a small wearable with photoplethysmography (PPG) sensors to measure heart rate and heart rate variability (HRV); accelerometers to measure movement, strain, and activity; and skin temperature sensors to capture variations during sleep or recovery. The new Whoop units are smaller and purportedly more power-efficient than the last one, although I'm not getting anywhere near the claimed 14-plus days of battery life. In 21 days, I've had to charge it twice. It doesn't have onboard GPS. It's not super-annoying, given that, you know, it doesn't even have a screen, so I'm not exactly using the Whoop to clock my pace on a run. But you do have to use GPS on your phone to unlock certain features within the Whoop app, like a more accurate VO 2 max. (Just toggle 'Track Route' in the app when starting to log a run.) You can also insert the Whoop into Whoop Body garments. Whoop sent the new MG training bra ($59) and training shorts ($54), which captured my data while I was running and rowing, but if you're a returning Whoop customer, you do need the new Whoop Body clothes because the MG is smaller than the last iteration, the Whoop 4.0. It's also important to note that Whoop changed its membership structure. You used to pay a blanket $30 per month membership fee for everything Whoop had to offer, but now features are paywalled behind a tiered subscription plan. Whoop One ($199/year) gets you the regular Whoop 5.0, which is the upgrade from the Whoop 4.0, Whoop Coach, and sleep, strain, and recovery tracking. Whoop Peak ($239/year) gets you the Whoop 5.0 with the new Healthspan and Pace of Aging features, and Whoop Life ($359/year) gets you the new Whoop MG, which unlocks the new cardiac features like ECGs, heart screeners, blood pressure monitoring, and AFib detection.
Yahoo
a day ago
- Yahoo
HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm
HeartSciences (HSCS) announced that the U.S. Food and Drug Administration has granted Breakthrough Device designationless than BDD, for its Aortic Stenosis ECG algorithm. The algorithm would offer a novel, AI-driven ECG solution capable of detecting moderate-to-severe aortic stenosis. Once cleared by the FDA, the algorithm will be accessible through HeartSciences' MyoVista Insights cloud-based platform which would directly integrate with hospital electronic health record systems, requiring no additional hardware or testing. This technology provides several key clinical advantages: Detection in asymptomatic or under-evaluated patients who may not yet show signs of AS; Real-time or retrospective analysis using existing ECG data already captured during routine care; Expanded access to early diagnosis, especially in underserved areas lacking specialized cardiac imaging or providers. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on HSCS: Disclaimer & DisclosureReport an Issue Heart Test Laboratories Files Certificate for Preferred Stock Heart Test Laboratories Secures Foundational Patent for AI-ECG HeartSciences announces grant by USPTO for ECG assessment of heart function HeartSciences signs first MyoVista Insights platform customer Heart Test Laboratories Announces $15M Securities Offering Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032
The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses like cancer, cardiovascular conditions, and lifestyle-related disorders. This momentum is further boosted by a rise in product innovation, growing global investments in digital health infrastructure, and a heightened focus on proactive, data-centric healthcare approaches. These trends are anticipated to significantly accelerate the expansion of the AI-enabled RPM market throughout the forecast period of 2025 to 2032. New York, USA, June 04, 2025 (GLOBE NEWSWIRE) -- Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses like cancer, cardiovascular conditions, and lifestyle-related disorders. This momentum is further boosted by a rise in product innovation, growing global investments in digital health infrastructure, and a heightened focus on proactive, data-centric healthcare approaches. These trends are anticipated to significantly accelerate the expansion of the AI-enabled RPM market throughout the forecast period of 2025 to 2032. DelveInsight's AI in Remote Patient Monitoring Market Insights report provides the current and forecast market analysis, individual leading AI in remote patient monitoring companies' market shares, challenges, AI in remote patient monitoring market drivers, barriers, trends, and key market AI in remote patient monitoring companies in the market. Key Takeaways from the AI in Remote Patient Monitoring Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in remote patient monitoring market during the forecast period. In the product type segment of the AI in remote patient monitoring market, the devices category held the largest revenue share in 2024. Notable AI in remote patient monitoring companies such as Medtronic, iRhythm Inc., Koninklijke Philips N.V., Siemens Healthineers, GE HealthCare, Apple Inc., AliveCor Inc., Biofourmis, Optum, Inc., Headspace Health, Withings, NeuroRPM Inc., Caretaker Medical, Implicity, Stryker, Biobeat, and several others are currently operating in the AI in remote patient monitoring market. In September 2024, iRhythm Technologies announced the Japanese regulatory approval of the zio® ECG monitoring system, the first product to deliver arrhythmia monitoring service utilizing artificial intelligence. In April 2024, Royal Philips, a global leader in health technology, announced a strategic partnership to integrate smartQare's advanced solution, viQtor, with Philips' world-leading clinical patient monitoring platforms. This collaboration aims to enable the next generation of continuous patient monitoring both in and out of the hospital, starting in Europe. To read more about the latest highlights related to the AI in remote patient monitoring market, get a snapshot of the key highlights entailed in the Global AI in Remote Patient Monitoring Market Report AI in Remote Patient Monitoring Overview Artificial intelligence (AI) is revolutionizing remote patient monitoring (RPM) by enabling real-time, continuous health surveillance outside of traditional clinical settings. Through wearable devices and connected sensors, AI algorithms can analyze vital signs, detect anomalies, and predict potential health deterioration before symptoms become critical. This proactive approach allows for early interventions, reduces hospital readmissions, and improves chronic disease management, particularly for conditions like heart failure, diabetes, and COPD. By automating data analysis and triage, AI also significantly reduces the burden on healthcare professionals, allowing them to focus on patients who need urgent attention. Furthermore, AI-driven RPM fosters personalized care by learning from individual patient data over time. Machine learning models can adapt to each patient's unique health patterns, improving the accuracy of predictions and enabling tailored treatment plans. Natural language processing (NLP) tools can also interpret patient-reported symptoms via apps or voice interfaces, enriching the clinical picture. As AI technologies evolve, their integration into RPM systems is expected to enhance accessibility, especially in rural or underserved areas, bridging gaps in healthcare delivery while maintaining cost-efficiency and high-quality in Remote Patient Monitoring Market Insights North America is projected to lead the AI in remote patient monitoring market from 2025 to 2032. This dominance is largely driven by factors such as the growing prevalence of chronic diseases like cancer, a robust healthcare infrastructure, widespread adoption of digital health technologies, and supportive government initiatives. The region also benefits from significant investments in digital health and the extensive use of wearable and connected medical devices. The rising incidence of cancer in the U.S. and Canada is fueling the demand for continuous, home-based care solutions. This trend is accelerating the adoption of AI-driven remote patient monitoring, which enhances treatment management, symptom tracking, and patient outcomes outside traditional healthcare settings. Additionally, the increasing rates of cardiovascular diseases and related risk factors are heightening the need for ongoing and efficient monitoring solutions. AI-powered remote monitoring enables early detection, real-time intervention, and personalized care for heart patients, particularly in aging populations, thereby reducing complications and improving outcomes. Together, these factors create a favorable landscape for market expansion, solidifying North America's position as the leading region in the AI-based remote patient monitoring market throughout the forecast period. To know more about why North America is leading the market growth in the AI in remote patient monitoring market, get a snapshot of the AI in Remote Patient Monitoring Market Outlook AI in Remote Patient Monitoring Market Dynamics The AI in remote patient monitoring market is undergoing rapid transformation, driven by the convergence of advanced technologies, shifting healthcare models, and an increasing emphasis on personalized care. Artificial Intelligence is enhancing RPM systems by enabling real-time data analysis, predictive analytics, and automation, thereby helping providers manage chronic diseases, post-operative care, and elderly patients more effectively. AI algorithms can analyze vast volumes of patient data from wearable devices and home-based monitoring systems, identifying anomalies and alerting care teams before a crisis occurs. This proactive capability is fueling demand, particularly in value-based care models where preventing hospital readmissions is key. One of the primary drivers of this market is the global increase in chronic diseases and aging populations, which has led to an urgent need for continuous and cost-effective patient monitoring. AI-based RPM solutions not only reduce the burden on healthcare systems but also empower patients to manage their conditions better. Furthermore, the COVID-19 pandemic accelerated adoption, normalizing virtual care and remote diagnostics. This shift has continued post-pandemic, with healthcare providers and payers increasingly investing in AI-driven tools to support hybrid care models and decentralize service delivery. However, the market is not without its challenges. Data privacy, regulatory hurdles, and interoperability issues are key barriers to widespread adoption. The effectiveness of AI algorithms depends heavily on access to high-quality, diverse datasets, and data silos across healthcare institutions can limit this. Additionally, regulatory frameworks are still evolving to keep pace with AI's rapid advancement, and there's ongoing scrutiny about algorithmic bias and accountability. Addressing these challenges is crucial for building trust among clinicians and patients alike. On the competitive front, the market is witnessing intense innovation and strategic partnerships among tech firms, medtech companies, and healthcare providers. Startups are emerging with specialized AI capabilities in areas like arrhythmia detection, diabetic monitoring, and mental health assessment, while major players are integrating AI into their existing RPM platforms. Cloud infrastructure providers and AI-as-a-service vendors are also playing a key role in scaling solutions across geographies. Looking ahead, the AI in RPM market is expected to experience sustained growth, driven by advances in sensor technology, 5G connectivity, and federated learning models that allow privacy-preserving data sharing. As AI becomes more explainable and transparent, its integration into clinical workflows will deepen, making remote monitoring an integral part of mainstream healthcare delivery. Get a sneak peek at the AI in remote patient monitoring market dynamics @ AI in Remote Patient Monitoring Market Dynamic Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Remote Patient Monitoring Market CAGR ~27% AI in Remote Patient Monitoring Market Size by 2032 USD 13.1 Billion Key AI in Remote Patient Monitoring Companies Medtronic, iRhythm Inc., Koninklijke Philips N.V., Siemens Healthineers, GE HealthCare, Apple Inc., AliveCor Inc., Biofourmis, Optum, Inc., Headspace Health, Withings, NeuroRPM Inc., Caretaker Medical, Implicity, Stryker, Biobeat, among others AI in Remote Patient Monitoring Market Assessment AI in Remote Patient Monitoring Market Segmentation AI in Remote Patient Monitoring Market Segmentation By Product Type: Devices, Software, and Services AI in Remote Patient Monitoring Market Segmentation By Application: Cancer, Cardiovascular Disorder, Lifestyle Disorders, and Others AI in Remote Patient Monitoring Market Segmentation By End User: Hospitals and Clinics, Diagnostic Centers, and Homecare Setting AI in Remote Patient Monitoring Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the AI in remote patient monitoring market are set to emerge as the trendsetter explore @ AI in Remote Patient Monitoring Companies Table of Contents 1 AI in Remote Patient Monitoring Market Report Introduction 2 AI in Remote Patient Monitoring Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Remote Patient Monitoring Market Key Factors Analysis 6 AI in Remote Patient Monitoring Market Porter's Five Forces Analysis 7 AI in Remote Patient Monitoring Market Layout 8 AI in Remote Patient Monitoring Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in remote patient monitoring market by 2032? Click to get a snapshot of the AI in Remote Patient Monitoring Market Trends Related Reports Patient Monitoring Devices Market Patient Monitoring Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key patient monitoring devices companies, including Medtronic plc, GE Healthcare, Philips Healthcare, Abbott Laboratories, Siemens Healthineers, Nihon Kohden Corporation, Masimo Corporation, Omron Healthcare Co., Ltd., Smiths Medical, Hillrom, Welch Allyn, Inc., Natus Medical Incorporated, Mindray Medical International Limited, Nonin Medical, Inc., Spacelabs Healthcare, among others. Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Precision Medicine Market Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Medical Imaging Market Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679
